Hemp Legally Speaking

Jonathan Miller interviews Chris Fontes, President of the US Hemp Authority about that organization's upcoming adult product certification program. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. Why did the US Hemp Authority decide to implement an adult product certification program?
2. What does the current marketplace look like for hemp products that potentially impair consumers?
3. How is the adult certification program different from the current non-intoxicating certification program?
4. How will this program help keep adult products out of the hands of children?
5. Why should a brand owner choose to certify their products through the program?
6. How should state and federal regulators take notice?

Jonathan Miller interviews Nolan Jackson, partner at Frost Brown Todd and regulatory counsel to the US Hemp Roundtable, about major legislative and regulatory changes being made at the state level during 2024. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. What is the impact of new laws passed by state legislatures in CT, SD, FL, GA, IA and TN?
2. What is the impact of new regulatory and administrative actions taken in DC, KY, and MD?
3. What is the status of legislation pending in CA, IL, LA and OH?
4. How can an individual or company keep apprised of the detailed changes being made on a regular basis in the states?

Jonathan Miller interviews Bill Bookout, President of the National Animal Supplements Council, about an exciting new study on the impact of hemp and CBD on household pets. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. What is the current marketplace for hemp supplements for pets?
2. How are pet owners finding value for administering hemp and CBD?
3. What were the results of the new study NASC commissioned on the use of hemp and CBD for pets?
4. How will this study shape future regulatory action from the FDA?
5. What advice do you give to pet owners on hemp and CBD pet products?

Jonathan Miller interviews Uttam Dhillon, the former Acting Administrator of the Drug Enforcement Administration and current partner at Frost Brown Todd, about federal law enforcement views of hemp and cannabis, and the potential rescheduling and descheduling of cannabis. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. As the DEA head when hemp was legalized, why was the agency so concerned about hemp prior to legalization?
2. What are the prospects of rescheduling cannabis, and what would serve as the regulatory framework?
3. Why is law enforcement so generally opposed to cannabis legalization?
4. Why does the DEA care about hemp/cannabis when there are so much more dangerous drugs affecting the country like heroin or fentanyl?
5. What are the most common misperceptions about DEA agent and their motivations?

Jonathan Miller interviews Jim Carroll, the former White House "Drug Czar" and current partner at Frost Brown Todd, about federal law enforcement views of hemp and cannabis, and the potential rescheduling of marijuana. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. How does federal law enforcement view cannabis and its potential legalization?
2. Are there more nuanced views toward hemp and CBD at the federal level?
3. What is the status of the Biden Administration's potential efforts to reschedule cannabis at Schedule 3, and what would it mean?
4. What would be an appropriate regulatory regime for cannabis under Schedule 3?
5. How should the cannabis industry prepare for rescheduling?
6. How would rescheduling impact hemp and hemp extracts?

Jonathan Miller interviews Deb Hackathorn, Frost Brown Todd principal and the U.S Hemp Roundtable's lobbyist in Columbus, about legislative efforts to ban certain hemp products in the Buckeye State. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. Ohioans passed a referendum in November to legalize adult-use marijuana.  What was the reaction of the Governor and legislature on its implementation?
2. What was the nature of legislation proposed in December that could have posed severe restrictions on hemp products in Ohio?
3. How did the hemp industry secure defeat of provisions that could have devastated Ohio farmers?
4. What are the Governor and legislature planning to do in the new year on these issues?
5. How can citizens make their voices heard in a meaningful way on this issue?

Jonathan Miller interviews CMDMd's Chief Science Officer Sibyl Swift and General Counsel Lance Blundell on the safety and future regulation of CBD.  If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. Is CBD safe?  From a legal perspective? From a scientific point of view?
2. Why does the FDA continue to caution the public about the safety of hemp extracts like CBD?
3. What are the steps Congress needs to take to ensure safe regulation of CBD?
4. How should Congress approach the issue of potentially-impairing cannabinoids like delta-8 THC?
5. What does Dr. Swift have to say about the growing #Swiftie movement?

Jonathan Miller interviews Rand Martin, the U.S Hemp Roundtable's lobbyist in Sacramento, about ongoing legislative and regulatory efforts to support (and burden) hemp products in California. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. What was in AB 45, the legislation that legalized CBD products in California, and how did it finally secure final passage?
2. How has the hemp smokable ban been addressed (or fail to be addressed) since passage of AB 45, and what are its prospects for the future?
3. How did recently introduced AB 420 intend to permit cannabis licensees to sell hemp products and what was the level of support for such a proposal?
4. When did AB 420 get enmeshed in the national debate over THC milligram limits on hemp products and what was the end result of the discussions?
5. What is the future of legislative and or regulatory policy when it comes to the treatment of full spectrum hemp products in California?

Jonathan Miller interviews his Frost Brown Todd colleague, Nolan Jackson, who serves as Regulatory Counsel for the US Hemp Roundtable, and the two discuss new state laws and regulations that have imposed restrictions on hemp and CBD products. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. Why are states beginning to impose THC milligram limits on hemp-derived CBD products?
2. What does the new New York regulatory regime mean for both the Empire State and the nation?
3. What other states are imposing THC milligram caps on CBD products and how do these states differ from each other?
4. Why is there a new trend to impose age restrictions on CBD products, and which states have implemented new laws or regulations in this space?
5. What should CBD manufacturers do to comply with these new state laws?
6. What are the prospects for state action in 2024?

Jonathan Miller interviews Rayetta Henderson, Senior Managing Scientist at Tox Strategies about her research and her testimony before the House Oversight Committee on the safety of hemp-derived CBD. If you have questions about the episode or ideas for Hemp related topics, email us at [email protected].

Hemp Industry questions covered in the episode: 

1. What were the results of your toxicology studies on the safety of CBD isolate?
2. How were thise results different from the studies championed by FDA concerning pharmaceutical-grade CBD found in the prescription drug Epidiolex?
3. Why are studies of rodents applicable to the experience of humans?
4. Have there been enough studies of CBD for FDA or Congress to be able to establish appropriate limits if CBD in dietary supplements and food/beverage?
5. What counsel to you give to Congress as they go about the process of drafting legislation to regulate CBD?